JP2005521723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005521723A5 JP2005521723A5 JP2003580276A JP2003580276A JP2005521723A5 JP 2005521723 A5 JP2005521723 A5 JP 2005521723A5 JP 2003580276 A JP2003580276 A JP 2003580276A JP 2003580276 A JP2003580276 A JP 2003580276A JP 2005521723 A5 JP2005521723 A5 JP 2005521723A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- amino
- disorders
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 14
- 125000001153 fluoro group Chemical group F* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 150000001875 compounds Chemical group 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 208000028017 Psychotic disease Diseases 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 206010012335 Dependence Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 230000003542 behavioural effect Effects 0.000 claims 4
- -1 chloro, fluoro, amino Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003176 neuroleptic agent Substances 0.000 claims 4
- 230000000701 neuroleptic effect Effects 0.000 claims 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 208000012661 Dyskinesia Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000016285 Movement disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 206010022437 insomnia Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- JXEHXYFSIOYTAH-UHFFFAOYSA-N 3-amino-5-methyloctanoic acid Chemical compound CCCC(C)CC(N)CC(O)=O JXEHXYFSIOYTAH-UHFFFAOYSA-N 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000036626 Mental retardation Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 206010020765 hypersomnia Diseases 0.000 claims 2
- JXEHXYFSIOYTAH-SFYZADRCSA-N imagabalin Chemical compound CCC[C@@H](C)C[C@H](N)CC(O)=O JXEHXYFSIOYTAH-SFYZADRCSA-N 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000018198 spasticity Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- GUEQOLSQPOTTME-RQJHMYQMSA-N (3s,5r)-3-amino-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](N)CC(O)=O GUEQOLSQPOTTME-RQJHMYQMSA-N 0.000 claims 1
- XKWDZEJCUWTBOM-BDAKNGLRSA-N (3s,5r)-3-amino-5-methylnonanoic acid Chemical compound CCCC[C@@H](C)C[C@H](N)CC(O)=O XKWDZEJCUWTBOM-BDAKNGLRSA-N 0.000 claims 1
- VNEAZJRSFULCJJ-YPMHNXCESA-N (3s,5r)-3-amino-7-cyclohexyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](N)C[C@H](C)CCC1CCCCC1 VNEAZJRSFULCJJ-YPMHNXCESA-N 0.000 claims 1
- HDLUMIBBUPOCSA-PWSUYJOCSA-N (3s,5r)-3-amino-7-cyclopentyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](N)C[C@H](C)CCC1CCCC1 HDLUMIBBUPOCSA-PWSUYJOCSA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- PVOZHPMILBKJAX-UHFFFAOYSA-N 3-amino-5-methyl-7-phenylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1=CC=CC=C1 PVOZHPMILBKJAX-UHFFFAOYSA-N 0.000 claims 1
- XKWDZEJCUWTBOM-UHFFFAOYSA-N 3-amino-5-methylnonanoic acid Chemical compound CCCCC(C)CC(N)CC(O)=O XKWDZEJCUWTBOM-UHFFFAOYSA-N 0.000 claims 1
- GSXLSVGQNPZFRS-UHFFFAOYSA-N 3-amino-7-(2,4-difluorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1=CC=C(F)C=C1F GSXLSVGQNPZFRS-UHFFFAOYSA-N 0.000 claims 1
- VNEAZJRSFULCJJ-UHFFFAOYSA-N 3-amino-7-cyclohexyl-5-methylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1CCCCC1 VNEAZJRSFULCJJ-UHFFFAOYSA-N 0.000 claims 1
- HDLUMIBBUPOCSA-UHFFFAOYSA-N 3-amino-7-cyclopentyl-5-methylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1CCCC1 HDLUMIBBUPOCSA-UHFFFAOYSA-N 0.000 claims 1
- FRXVVOBOAUAOCA-UHFFFAOYSA-N 3-amino-8-(2,3-difluorophenyl)-5-methyloctanoic acid Chemical compound OC(=O)CC(N)CC(C)CCCC1=CC=CC(F)=C1F FRXVVOBOAUAOCA-UHFFFAOYSA-N 0.000 claims 1
- WXJZPMQTLWNDGI-UHFFFAOYSA-N 3-amino-8-(2,4-difluorophenyl)-5-methyloctanoic acid Chemical compound OC(=O)CC(N)CC(C)CCCC1=CC=C(F)C=C1F WXJZPMQTLWNDGI-UHFFFAOYSA-N 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010068631 Childhood depression Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010016275 Fear Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 206010049949 Intercostal neuralgia Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000006199 Parasomnias Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010073211 Postural tremor Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 1
- 206010038743 Restlessness Diseases 0.000 claims 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 1
- 201000000552 Scott syndrome Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 206010040744 Sinus headache Diseases 0.000 claims 1
- 206010041247 Social fear Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000001407 Vascular Headaches Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 239000000380 hallucinogen Substances 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 206010021654 increased appetite Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 230000010355 oscillation Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229940053982 other anxiolytics in atc Drugs 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36841302P | 2002-03-28 | 2002-03-28 | |
| PCT/IB2003/000976 WO2003082807A2 (en) | 2002-03-28 | 2003-03-17 | Amino acids with affinity for the alpha-2-delta-protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005218738A Division JP3857714B2 (ja) | 2002-03-28 | 2005-07-28 | α２δ−タンパク質へのアフィニティを有するアミノ酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005521723A JP2005521723A (ja) | 2005-07-21 |
| JP2005521723A5 true JP2005521723A5 (https=) | 2006-01-12 |
| JP3831379B2 JP3831379B2 (ja) | 2006-10-11 |
Family
ID=28675482
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003580276A Expired - Fee Related JP3831379B2 (ja) | 2002-03-28 | 2003-03-17 | α２δ−タンパク質へのアフィニティを有するアミノ酸 |
| JP2005218738A Expired - Fee Related JP3857714B2 (ja) | 2002-03-28 | 2005-07-28 | α２δ−タンパク質へのアフィニティを有するアミノ酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005218738A Expired - Fee Related JP3857714B2 (ja) | 2002-03-28 | 2005-07-28 | α２δ−タンパク質へのアフィニティを有するアミノ酸 |
Country Status (42)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10129693A1 (de) * | 2001-06-22 | 2003-01-02 | Jan Loock | Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums |
| NI200300043A (es) * | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| BRPI0414798A (pt) | 2003-09-25 | 2006-11-21 | Warner Lambert Co | métodos para usar aminoácidos com afinidade para a proteìna alfa2delta |
| BRPI0414781A (pt) | 2003-09-25 | 2006-11-21 | Warner Lambert Co | aminoácidos com afinidade para a proteìna (alfa)2(delta) |
| RU2335342C2 (ru) * | 2004-03-12 | 2008-10-10 | Уорнер-Ламберт Компани Ллс | C1-симметричные бисфосфиновые лиганды и их применение в асимметрическом синтезе прегабалина |
| US20090247743A1 (en) * | 2004-07-09 | 2009-10-01 | Pfizer Inc | Preparation of beta-amino acids having affinity for the alpha-2-delta protein |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| KR20070107147A (ko) * | 2005-03-24 | 2007-11-06 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알파-2-델타 단백질에 친화성을 갖는 광학적으로 순수한베타-아미노산의 제조 |
| WO2007052134A1 (en) * | 2005-11-04 | 2007-05-10 | Pfizer Limited | (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use |
| US20090286875A1 (en) * | 2005-11-17 | 2009-11-19 | Pfizer, Inc. | Isocystene derivatives for the treatment of pain |
| CN101420947A (zh) * | 2006-03-06 | 2009-04-29 | 辉瑞产品公司 | 用于非恢复性睡眠的α-2-δ配体 |
| AR061728A1 (es) * | 2006-06-30 | 2008-09-17 | Pfizer Prod Inc | Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1 |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| CA2836449C (en) | 2011-05-17 | 2021-04-27 | The Regents Of The University Of California | Kinase inhibitors |
| EA025496B1 (ru) | 2011-05-17 | 2016-12-30 | Принсипиа Биофарма Инк. | Ингибиторы тирозинкиназы |
| US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| CN103164756A (zh) * | 2011-12-12 | 2013-06-19 | 苏州艾隆科技有限公司 | 贵重药品的管理方法及其系统 |
| ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
| US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| MA45547A (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
| TWI877239B (zh) | 2019-10-14 | 2025-03-21 | 美商普林斯匹亞生物製藥公司 | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法 |
| JP2023511105A (ja) | 2020-01-22 | 2023-03-16 | プリンシピア バイオファーマ インコーポレイテッド | ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態 |
| WO2025078915A1 (en) * | 2023-10-12 | 2025-04-17 | Siemens Healthcare Diagnostics Inc. | Pregabalin haptens, immunogens, and protein conjugates and methods of production and use thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1377736A (fr) * | 1962-12-21 | 1964-11-06 | Hoffmann La Roche | Procédé pour la préparation d'acides amino-carboxyliques |
| FR1377366A (fr) | 1963-08-19 | 1964-11-06 | Dispositif de protection de sécurité pour appareils électriques | |
| KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| AU7168091A (en) | 1989-12-22 | 1991-07-24 | Schering Corporation | Mercaptocycloacyl aminoacid endopeptidase inhibitors |
| US5614498A (en) | 1990-06-07 | 1997-03-25 | Banyu Pharmaceutical Co., Ltd. | Endothelin antagonistic substance |
| US5011066A (en) * | 1990-07-27 | 1991-04-30 | Motorola, Inc. | Enhanced collapse solder interconnection |
| US5239113A (en) | 1991-10-15 | 1993-08-24 | Monsanto Company | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof |
| EP0561758A3 (en) | 1992-03-18 | 1995-04-05 | Monsanto Co | Method of preparing optically active homo-beta-amino acids |
| US5578606A (en) * | 1992-10-30 | 1996-11-26 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
| CA2176140A1 (en) | 1993-11-24 | 1995-06-01 | Meng Hsin Chen | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
| JPH09506369A (ja) | 1993-12-12 | 1997-06-24 | アグロジーン・リミテッド | 菌類感染から植物を保護するための新規方法 |
| US5472830A (en) | 1994-04-18 | 1995-12-05 | Ocg Microelectronic Materials, Inc. | Non-corrosion photoresist stripping composition |
| JP2000514809A (ja) | 1996-07-12 | 2000-11-07 | ジー．ディー．サール アンド カンパニー | キラルβ―アミノ酸の不斉合成 |
| ATE361909T1 (de) * | 1996-10-23 | 2007-06-15 | Warner Lambert Co | Substituierte gamma-aminobuttersäurederivate als arzneimittel |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| GB2323594A (en) | 1997-03-25 | 1998-09-30 | Victor Martin | 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| US6011066A (en) | 1998-02-02 | 2000-01-04 | Veterans General Hospital-Taipei | Method for treating septic shock |
| CN1297354A (zh) | 1998-03-16 | 2001-05-30 | 西托维亚公司 | 二肽卡斯帕酶抑制剂及其用途 |
| EP1013769A1 (en) | 1998-12-22 | 2000-06-28 | Dsm N.V. | Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity |
| FR2791982B1 (fr) | 1999-04-06 | 2002-12-27 | Inst Nat Sante Rech Med | Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques. |
| ES2317839T3 (es) * | 1999-06-10 | 2009-05-01 | Warner-Lambert Company Llc | Acidos 3-propil gamma-aminobutiricos monosustituidos. |
| JP2003533223A (ja) * | 2000-05-16 | 2003-11-11 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | α２δ２カルシウムチャネルサブユニットの発現細胞株 |
| EP1282594A1 (en) | 2000-05-17 | 2003-02-12 | Medivir UK Ltd | Branched amino acids |
| MXPA03002090A (es) | 2000-09-14 | 2003-06-19 | Gruenenthal Gmbh | °-tio-aminoacidos. |
| DE10048715A1 (de) | 2000-09-30 | 2004-05-19 | Grünenthal GmbH | Verwendung von Aminosäure zur Behandlung von Schmerz |
| CA2440834A1 (en) * | 2001-03-13 | 2002-09-19 | Queen's University At Kingston | Anti-epileptogenic agents |
| NI200300043A (es) * | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| CN1228312C (zh) * | 2002-12-27 | 2005-11-23 | 中国科学院化学研究所 | 以酮为原料合成β—氨基酸的方法 |
-
2003
- 2003-03-06 NI NI200300043A patent/NI200300043A/es unknown
- 2003-03-17 HR HRP20040891 patent/HRP20040891A2/hr not_active Application Discontinuation
- 2003-03-17 EP EP03706831A patent/EP1492761B1/en not_active Expired - Lifetime
- 2003-03-17 OA OA1200400254A patent/OA12795A/en unknown
- 2003-03-17 DK DK03706831T patent/DK1492761T3/da active
- 2003-03-17 ES ES03706831T patent/ES2327910T3/es not_active Expired - Lifetime
- 2003-03-17 AP APAP/P/2004/003144A patent/AP1791A/en active
- 2003-03-17 KR KR1020057025293A patent/KR100694719B1/ko not_active Expired - Fee Related
- 2003-03-17 UA UA20040907854A patent/UA80116C2/uk unknown
- 2003-03-17 IL IL16411003A patent/IL164110A0/xx unknown
- 2003-03-17 GE GEAP20038907A patent/GEP20084298B/en unknown
- 2003-03-17 WO PCT/IB2003/000976 patent/WO2003082807A2/en not_active Ceased
- 2003-03-17 SI SI200331654T patent/SI1492761T1/sl unknown
- 2003-03-17 EP EP05108848A patent/EP1614675A3/en not_active Withdrawn
- 2003-03-17 CN CNA2006100070283A patent/CN1817854A/zh active Pending
- 2003-03-17 PL PL373363A patent/PL209750B1/pl not_active IP Right Cessation
- 2003-03-17 RS YUP-836/04A patent/RS83604A/sr unknown
- 2003-03-17 CA CA2480872A patent/CA2480872C/en not_active Expired - Fee Related
- 2003-03-17 AU AU2003208538A patent/AU2003208538B2/en not_active Ceased
- 2003-03-17 HR HR20050764A patent/HRP20050764A2/hr not_active Application Discontinuation
- 2003-03-17 GE GEAP8423A patent/GEP20074123B/en unknown
- 2003-03-17 MX MXPA04009373A patent/MXPA04009373A/es active IP Right Grant
- 2003-03-17 NZ NZ541320A patent/NZ541320A/en unknown
- 2003-03-17 CN CNB038112698A patent/CN100462351C/zh not_active Expired - Fee Related
- 2003-03-17 JP JP2003580276A patent/JP3831379B2/ja not_active Expired - Fee Related
- 2003-03-17 BR BR0308814-6A patent/BR0308814A/pt active Search and Examination
- 2003-03-17 NZ NZ535364A patent/NZ535364A/en not_active IP Right Cessation
- 2003-03-17 DE DE60328469T patent/DE60328469D1/de not_active Expired - Lifetime
- 2003-03-17 PT PT03706831T patent/PT1492761E/pt unknown
- 2003-03-17 KR KR1020047015361A patent/KR100630981B1/ko not_active Expired - Fee Related
- 2003-03-17 UA UAA200507455A patent/UA80018C2/uk unknown
- 2003-03-17 RS YUP-2005/0667A patent/RS20050667A/sr unknown
- 2003-03-17 EA EA200501497A patent/EA200501497A1/ru unknown
- 2003-03-17 EA EA200401127A patent/EA008709B1/ru unknown
- 2003-03-24 TW TW092106516A patent/TWI225864B/zh not_active IP Right Cessation
- 2003-03-25 PE PE2003000303A patent/PE20040349A1/es not_active Application Discontinuation
- 2003-03-25 MY MYPI20031051A patent/MY131424A/en unknown
- 2003-03-26 AR ARP030101060A patent/AR039154A1/es not_active Application Discontinuation
- 2003-03-27 UY UY27738A patent/UY27738A1/es not_active Application Discontinuation
- 2003-03-27 US US10/401,060 patent/US7064147B2/en not_active Expired - Lifetime
- 2003-03-28 GT GT200300072AK patent/GT200300072AA/es unknown
- 2003-03-28 PA PA20038570001A patent/PA8570001A1/es unknown
- 2003-03-28 GT GT200300072A patent/GT200300072A/es unknown
-
2004
- 2004-09-16 IS IS7451A patent/IS7451A/is unknown
- 2004-09-17 ZA ZA2004/07536A patent/ZA200407536B/en unknown
- 2004-09-24 MA MA27874A patent/MA27188A1/fr unknown
- 2004-09-27 CU CU20040212A patent/CU23331B7/es not_active IP Right Cessation
- 2004-09-27 TN TNP2004000186A patent/TNSN04186A1/fr unknown
- 2004-09-28 EC EC2004005319A patent/ECSP045319A/es unknown
- 2004-09-28 CR CR7501A patent/CR7501A/es unknown
- 2004-10-26 NO NO20044614A patent/NO20044614L/no not_active Application Discontinuation
-
2005
- 2005-07-01 US US11/173,073 patent/US20050272783A1/en not_active Abandoned
- 2005-07-20 AR ARP050102999A patent/AR050261A2/es unknown
- 2005-07-21 IL IL169820A patent/IL169820A0/en unknown
- 2005-07-21 IS IS7951A patent/IS7951A/is unknown
- 2005-07-28 JP JP2005218738A patent/JP3857714B2/ja not_active Expired - Fee Related
- 2005-08-23 NO NO20053918A patent/NO20053918L/no not_active Application Discontinuation
-
2006
- 2006-03-14 US US11/375,318 patent/US7517909B2/en not_active Expired - Fee Related
-
2009
- 2009-08-12 CY CY20091100858T patent/CY1109304T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005521723A5 (https=) | ||
| CA2480872A1 (en) | Amino acids with affinity for the .alpha.-2-.delta.-protein | |
| JP5815644B2 (ja) | オキサジアゾール誘導体およびそれらの代謝型グルタミン酸受容体増強剤としての使用 | |
| JP4193949B2 (ja) | Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド | |
| JP6681451B2 (ja) | Ｂａｃｅ１阻害剤 | |
| JP2008510808A (ja) | ヒスタミンｈ３受容体薬剤、製剤及び治療的使用 | |
| JP2010503656A (ja) | スピロ−オキサゾリジノン化合物と代謝共役型グルタミン酸受容体ポテンシエーターとしてのその使用 | |
| JP2008509982A (ja) | アリール尿素誘導体 | |
| ES2395304B1 (es) | Procedimiento de obtención de una tiofen-2-carboxamida. | |
| TW201211037A (en) | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | |
| JPH11509835A (ja) | 炎症を治療するための置換オキサゾール | |
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| US9725463B2 (en) | Substituted heterocyclic compounds as CRAC modulators | |
| EA022649B1 (ru) | ПРОИЗВОДНЫЕ 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
| JP2011510083A (ja) | ３，５−二置換−１，３−オキサゾリジン−２−オン誘導体 | |
| JP2013541596A5 (https=) | ||
| US11541057B2 (en) | Thienopyrimidinone NMDA receptor modulators and uses thereof | |
| JP2009519929A (ja) | オキサゾリジノン化合物及び代謝型グルタミン酸レセプター増強剤としてのそれらの使用 | |
| WO2008150492A1 (en) | Tricyclic inhibitors of fatty acid amide hydrolase | |
| CA2720490A1 (en) | Compounds and compositions as itpkb inhibitors | |
| JP2007501826A (ja) | キノリン４−カルボキサミド誘導体およびニューロキニン３（ｎｋ−３）受容体アンタゴニストとしてのその使用 | |
| JP2006516589A (ja) | Ｃｃｒ２受容体拮抗薬としてのメルカプトイミダゾール | |
| WO2007121389A2 (en) | 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors | |
| Jain et al. | Menthone aryl acid hydrazones: a new class of anticonvulsants | |
| JP2021529813A (ja) | チアジアジン誘導体 |